Work

Why are immune adverse events so common with checkpoint inhibitor therapy?

Year: 2021

Type: article

Source: Annals of Allergy Asthma & Immunology

DOI: 10.1016/j.anai.2021.03.016

Authors: Taras Lyubchenko, Donald Y.M. Leung, Elena Goleva

Institutions: University of Denver, National Jewish Health

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases

Awards: G8589387000, SEAL (Stopping Atopic dermatitis and ALlergy) Study: Prevent allergy by enhancing the skin barrier

OpenAlex ID: W3141892070

FWCI: 0.489

Cites: 5

Cited by: 7

Related to: 10